Michael Donohue, PhD is an Associate Professor of Neurology, Associate Director of Biostatistics at the Alzheimer's Therapeutic Research Institute (ATRI), and Co-Lead of the Biostatistics Unit of the Alzheimer's Clinical Trial Consortium (ACTC).
Since obtaining his PhD in Mathematics in 2005, Dr. Donohue has worked on Alzheimer’s clinical trials and observational studies, such as the Alzheimer’s Disease Neuroimaging Initiative (ADNI). His primary area of interest is applying novel statistical methods to data from ADNI to better understand the multivariate course of markers of Alzheimer’s progression, and design innovative clinical trials to prevent or slow the progression of disease. He has studied the risk of cognitive decline associated with elevated brain amyloid in cognitively normal individuals; and helped design the first intervention in asymptomatic Alzheimer’s, the Anti-Amyloid Treatment for Asymptomatic Alzheimer’s (the A4 Study; in collaboration with Eli Lilly), and its primary outcome measure, the Preclinical Alzheimer Cognitive Composite. He has been awarded grants to develop innovative statistical approaches for Alzheimer’s from the National Institute on Aging; the Alzheimer's Association, Michael J. Fox Foundation, and W. Garfield Weston Foundation; and the Clinical and Translation Research Institute of University of California, San Diego